Krystal Biotech subsidiary Jeune reports 100% investigator-rated GAIS improvement in Phase 1 KB304 study

Krystal Biotech, Inc.

PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.
81.8% of KB304 subjects reported improved satisfaction on SSQ at 3 months vs 14.3% for placebo; improvements also seen in elasticity, crepiness, hydration, radiance.
Safety consistent with prior KB301 experience: no severe or drug-related serious AEs; AEs mild-to-moderate and decreased with subsequent doses.
Company plans to meet with FDA in H2 2025 to align on Phase 2 protocol; target Phase 2 start in H1 2026 for décolleté wrinkles.
KB304 is first candidate to combine collagen (COL3) and elastin delivery via gene therapy to restore skin naturally.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.